USP <1211>: The Compendial Informational Chapter on Sterility Assurance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP <1211>: The Compendial Informational Chapter on Sterility Assurance
The author provides a history of the information chapter USP 91211: "Sterilization and Sterility Assurance of Compendial Articles," from the early 1900s to the current version.


Pharmaceutical Technology


Acknowledgment

The author would like to acknowledge and thank the contributions of Radhakrishna Timuralai and James Agalloco to the completion of this article.

Scott Sutton, PhD, is a consultant at Vectech Pharmaceutical Consultants, tel. 585.594.8273,

References

1. L. Anderson and G.J. Higby, The Spirit of Volunteerism: A Legacy of Commitment and Contribution. The United States Pharmacopeia 1820–1995 (US Pharmacopeial Convention, Rockville, MD, 1995).

2. USP IX, "Sterilization," pp. 616–617 (1916).

3. W.M. Heller, "USP and the Drug Regulation Reform Act," PDA J. Paren. Drug Assoc. 33 (2), 55–60 (1979).

4. B. Immel, "A Brief History of the GMPs," BioPharm 15 (8), 18–24 (2000).

5. "Drugs: Current Good Manufacturing Practice in Manufacture, Processing, Packing or Holding," Federal Register 28 Part 133, p. 6385 (June 20, 1963).

6. P. Shadle, "Overview of GMPs," Biopharm Intl. 18 (11), 8–14 (2004).

7. B. Matthews, "The Devonport Incident, the Clothier Report, and Related Matters: 30 Years On," PDA J. Pharm Sci. Technol. 56 (3), 137–149 (2002).

8. USP XIII, "Sterilization Processes," pp. 692–699 (1947).

9. S. Sutton, "Sterilization" in Pharmaceutical Quality Control Microbiology: A Guidebook to the Basics (DHI Publishers, 2007).

10. USP XVI, "Sterilization," pp. 839–841 (1960).

11. USP XVII, "Sterilization," pp. 810-814 (1965).

12. USP XVII, "Sterilization," pp. 830–835 (1970).

13. USP XIX "Sterilization," pp. 709–714 (1975).

14. USP XIX "Sterility Tests," pp. 592–595 (1975).

15. USP XX Chapter ‹1211›, "Sterilization," pp. 1037–1040 (1980)

16. USP XX Chapter ‹71›, "Sterility Tests," pp. 878–882 (1980).

17. "‹1211› Sterilization and Sterility Assurance of Compendial Articles," Pharm Forum 8 (3), 2073–2088 (1982).

18. "‹1211› Sterilization and Sterility Assurance of Compendial Articles," Pharm Forum. 9 (3), 2958–2971 (1983).

19. "‹1211› Sterilization and Sterility Assurance of Compendial Articles," Pharm Forum. 9 (5), 3513-3526.

20. USP XXI Chapter ‹1211›, "Sterilization and Sterility Assurance of Compendial Articles," pp. 1347–1352 (1985).

21, "‹1211› Sterilization and Sterility Assurance of Compendial Articles," Pharm Forum. 12 (2), 1221 (1986).

22. "‹71› Sterility Tests," Pharm Forum. 12 (4), 1604–1605 (1986).

23. USP XXII Chapter ‹1211›, "Sterilization and Sterility Assurance of Compendial Articles," pp. 1705–1710 (1990).

24. "‹1211› Sterilization and Sterility Assurance of Compendial Articles," Pharm Forum. 16 (4), 687–689 (1990).

25. USP 23 Chapter ‹1211›, "Sterilization and Sterility Assurance of Compendial Articles," pp. 1976–1981 (1995).

26. J.E. Akers and J. Agalloco, "Sterility and Sterility Assurance," PDA J Pharm Sci Tech. 51 (2), 72–77 (1997).

27. S.V.W. Sutton, J.E. Knapp, and R. Dabbah, "Activities of the USP Microbiology Subcommittee of Revision During the 1995–2000 Revision Cycle," PDA J Pharm Sci Technol. 55 (1), 33–48 (2001).

28. "‹1211› Sterilization and Sterility Assurance of Compendial Articles," Pharm Forum. 30 (5), 1729–1739 (2004).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here